Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
Evotec SE has announced it will release its financial results for the first nine months of 2024 on Wednesday, November 6, 2024. The company will host a conference call at 2:00 PM CET to discuss the nine-month results and provide updates on their ongoing priority reset and strategic review process. The call will be conducted in English and will include both a webcast and phone-in options. Participants can access presentation slides and register for the audio webcast through provided links. An on-demand version will be available on Evotec's website after the event.
Evotec SE ha annunciato che pubblicherà i risultati finanziari per i primi nove mesi del 2024 il mercoledì 6 novembre 2024. L'azienda terrà una conferenza telefonica alle 14:00 CET per discutere i risultati dei nove mesi e fornire aggiornamenti sul ripristino delle priorità e sul processo di revisione strategica in corso. La chiamata si svolgerà in inglese e includerà sia un webcast che opzioni di accesso telefonico. I partecipanti possono accedere alle diapositive della presentazione e registrarsi per il webcast audio tramite i link forniti. Una versione on-demand sarà disponibile sul sito web di Evotec dopo l'evento.
Evotec SE ha anunciado que publicará sus resultados financieros para los primeros nueve meses de 2024 el miércoles 6 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica a las 2:00 PM CET para discutir los resultados de los nueve meses y proporcionar actualizaciones sobre su reinicio de prioridades y el proceso de revisión estratégica en curso. La llamada se realizará en inglés e incluirá opciones tanto de webcast como de llamada telefónica. Los participantes pueden acceder a las diapositivas de la presentación y registrarse para el webcast de audio a través de los enlaces proporcionados. Una versión bajo demanda estará disponible en el sitio web de Evotec después del evento.
Evotec SE는 2024년 첫 9개월 동안의 재무 결과를 2024년 11월 6일 수요일에 발표할 것이라고 밝혔습니다. 회사는 오후 2시 CET에 9개월 결과에 대해 논의하고 그들의 우선순위 재설정 및 전략 검토 과정에 대한 업데이트를 제공하기 위해 컨퍼런스 콜을 개최할 예정입니다. 콜은 영어로 진행되며, 웹캐스트 및 전화 참여 옵션이 모두 포함됩니다. 참가자는 제공된 링크를 통해 발표 슬라이드에 접근하고 오디오 웹캐스트를 등록할 수 있습니다. 이벤트 후 Evotec의 웹사이트에서 주문형 버전을 이용할 수 있습니다.
Evotec SE a annoncé qu'elle publiera ses résultats financiers pour les neuf premiers mois de 2024 le mercredi 6 novembre 2024. La société organisera une conférence téléphonique à 14h00 CET pour discuter des résultats des neuf mois et fournir des mises à jour sur la réinitialisation de ses priorités et le processus de révision stratégique en cours. L'appel sera effectué en anglais et comprendra à la fois des options de webdiffusion et de participation par téléphone. Les participants peuvent accéder aux diapositives de la présentation et s'inscrire pour le webdiffusion audio via les liens fournis. Une version à la demande sera disponible sur le site Web d'Evotec après l'événement.
Evotec SE hat angekündigt, dass die Finanzergebnisse für die ersten neun Monate des Jahres 2024 am Mittwoch, den 6. November 2024 veröffentlicht werden. Das Unternehmen wird um 14:00 Uhr CET eine Telefonkonferenz abhalten, um die Ergebnisse der neun Monate zu diskutieren und Updates zu ihrem laufenden Prioritätenset und dem strategischen Überprüfungsprozess zu geben. Der Anruf wird auf Englisch durchgeführt und beinhaltet sowohl eine Webcast- als auch eine Telefonoption. Teilnehmer können auf die Präsentationsfolien zugreifen und sich über die bereitgestellten Links für den Audio-Webcast registrieren. Eine On-Demand-Version wird nach der Veranstaltung auf der Website von Evotec verfügbar sein.
- None.
- None.
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.
Webcast details
Date: Wednesday, 06 November 2024
Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications.
Conference call details
To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialling in via phone is available under this link.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
When will Evotec SE (EVO) release its Q1-Q3 2024 financial results?
What time is Evotec's (EVO) Q3 2024 earnings call?
What topics will be covered in Evotec's (EVO) November 2024 earnings call?
